no$gba download android

no$gba download android 1 2 Ranchi: Hoping to wrest Jharkhand from the Hemant Soren-led JMM govt, the BJP went to the polls with a strong strategy of showcasing cases of poor tribals losing their land to Bangladeshi land grabbers, in a move that eventually backfired with the entire campaign getting lost in translation on ground. And the result was JMM in its bastion of Santhal Pargana clinched all 18, but one seat with the help of its partners BJP got reduced from four seats in 2019 to one this time while the JMM bagged 11, Congress four and RJD two. Devendra Kunwar is the only BJP man in Santhal's Jarmundi seat. The idea was to examine how much of tribal land had changed hands from tribals over the past few decades and star BJP campaigner Himanta Biswa Sarma highlighting how JMM was becoming a stumbling block. Turns out, many tribals in the region, reeling under abject poverty were signing daan patras (tribal land is legally non-transferable) to hand over their non-saleable land to local Muslims to run a business and getting paid in return. Almost the entire Santhal Pargana region is governed by Santhal Pargana Tenancy Act of 1876 under which not even an inch of tribal land is transferable. This renders the tribals poor, especially when they are unable to practice farming. Under tacit local understanding they write off their land for a small price to local Muslim families and also get some money annually when it's the time to pay land revenue. Maharashtra Jharkhand Maharashtra Alliance View i Party View Seats: 288 Results Majority: 145 BJP+ 229 MVA 47 OTH 12 Results : 288 / 288 BJP+ WON Jharkhand Alliance View i Party View Seats: 81 Results Majority: 41 INDIA 56 NDA 24 OTH 1 Results : 81 / 81 INDIA WON Source: PValue As polls neared and campaigning got hectic, the narrative somewhere got lost in translation and turned out to be "ghuspethiyas" (infiltrators) crossing the Bangladesh border through West Bengal's Murshidabad and grabbing land, livelihoods and even Adivasi women. What followed next was a poll cry of –roti, beti and maati (vote to save employment options, daughters and land being grabbed by infiltrators) The ruling JMM-Congress combine countered saying BJP was spoiling communal harmony, creating a divide between locals and creating unnecessary fear when the reality was something else. "Himanta Biswa Sarma is quite an artist. There is always communal talk. We don't share a border with Bangladesh and the border in West Bengal is guarded by central forces," thundered CM Hemant Soren. The Muslims of Jharkhand, who are residents for decades and the tribals wondered each time a BJP leader came asking for a "ghuspetia". "This is laughable, they are trying to find out about ghuspetias. Are we infiltrators? The tribals and Muslim local residents are a happy lot. We even had the odd love marriages," said Asharful Sheikh who married Jharna Marandi, now pradhan of Nartanpur village As the date of election approached, the local BJP leaders dropped the "ghuspetias" angle in their campaign and soon, AJSU party, an ally of the NDA dropped infiltration from their manifesto. "Yaha ghuspetias wala baat nahi chalega," said Alamgir Alam, district president of Ajsu party in Pakur, who was overlooking the campaign for his party candidate Azhar Islam. He along with the BJP poll incharge denied infiltration being any issue. "Let the leaders talk about it for the national audience, we know the ground reality here," Alam added. The result was clear as the JMM led INDIA bloc routed the BJP from the 27 (JMM-21, Congress-6) of 28 ST seats. Former CM Champai Soren emerged as the only legislator of the saffron camp to be elected from ST reserved seat (Seraikela). The INDIA bloc's strong performance across the seats indicated that the BJP's politics did not resonate among the tribal electorate. Nalin Soren, the incumbent Dumka MP who represented Shikaripara (ST) assembly segment until this year's Lok Sabha election, claimed that the tribal electorate rejected the BJP's politics of communalism and hatred in this election. "Several factors resulted in a good show. While there was the benefit of the social welfare schemes such as Maiyya Samman and Savitri Bai Phule Yojana, there was considerable discontent among the electorate because the BJP led government at the Centre did not act on the Sarna Code. Today's results proved that the tribal community has rallied strongly behind Hemant Soren," he told TOI in Dumka.James Politi , Felicia Schwartz , Stefania Palma and Aime Williams in Washington Your guide to what the 2024 US election means for Washington and the world Joe Biden is staging a final push to deliver more aid to Ukraine, lock in manufacturing subsidies and confirm federal judges as he tries to secure his legacy before Donald Trump starts his second term in January. Following vice-president Kamala Harris’s defeat to Trump this month, and the failure of his own re-election bid in July, Biden has been urging his cabinet and senior officials to ramp up, rather than wind down, their activities. For many administration officials, the push to double down on domestic and foreign policy initiatives is an attempt to preserve some of their biggest accomplishments and head off Trump’s attempts to reverse them. “The president has been very clear that we need to get as much done as possible, and he wants it to be as productive a period as other periods in his presidency,” a White House official said on Friday. On the global stage, Biden is still grappling with the Russia-Ukraine conflict and Israel’s wars with Hamas in Gaza and Hizbollah in Lebanon, both of which have weighed heavily on his presidency. In a flurry of last-minute decisions, Biden and his team have taken steps to help Kyiv strengthen its position on the battlefield, ultimately improving its leverage in negotiations with Russia over a settlement that might now come sooner rather then later. Trump, a sceptic of Ukraine aid, has pledged to end the war between Russia and Ukraine quickly, and vice president-elect JD Vance outlined a plan on the campaign trail in which Russia would hold on to the territory it has taken. But the Biden administration is still trying to give one last jolt of help to Ukraine, including a surge of $7bn in lethal aid and significant policy shifts regarding the use of US-provided weapons. Notably, the US has approved Kyiv’s use of long-range weapons for deep strikes into Russian territory and will transfer anti-personnel mines to Ukraine. In the Middle East, Biden has failed to achieve his goal of securing a ceasefire deal between Israel and Gaza that could lead to the release of the remaining hostages held by Hamas — and there is scant hope that could be reached within the next two months. But Biden has set his sights on halting the fighting between Israel and Hizbollah, dispatching Amos Hochstein , a senior aide, to the region, though it is also a long-shot. The aim is to allow tens of thousands of displaced Israelis to return to their homes on the Israel-Lebanon border and for Hizbollah to move its forces away from the contested area. At home, the strong jobs growth under Biden’s watch fell flat with voters, who punished Harris over his administration’s record on inflation even though price gains have eased since their peak in 2022. Biden’s main goal now is to make sure that the hundreds of billions of dollars in investments he enacted to spur domestic manufacturing and infrastructure upgrades — from chip production to clean energy plants — can live on in the second Trump era. “We’re really mobilising on . . . getting projects online, getting funding out the door, making sure that we execute as much as we can on the different legislation that the president passed,” the White House official said. Gina Raimondo, Biden’s commerce secretary, has said she aims to spend “almost all” of the $50bn earmarked to supercharge US chip manufacturing under Biden’s Chips Act, of which $39bn is directed to incentives and $11bn is for research and development. In a recent interview with Politico, Raimondo said she directed her staff to work through the weekend and made personal calls to tech company executives to try and speed up deals. “The chips team has announced preliminary agreements with two dozen companies for chips awards, and over the next two months, plans to announce preliminary agreements for all $39bn of that funding, and is well on its way towards securing final agreements for many of those entities [where] preliminary awards were announced,” another White House official said. Meanwhile, Biden’s top climate officials have sought to reassure allies that Donald Trump will not be able to halt the progress of Biden’s flagship Inflation Reduction Act, which contains $369bn in subsidies for clean technologies. John Podesta, Biden’s top climate adviser, told delegates at this month’s UN climate summit that he believed Republicans would not try to reverse the IRA because the subsidies helped companies set up factories in red states. “Many Republicans, especially governors, know all this activity is a good thing for their districts, states and for their economies,” said Podesta. But the other big domestic priority for Biden is to press the Senate — which will be controlled by Democrats until early January — to confirm as many of his judicial appointments as possible before Trump is able to usher in a new wave of conservative nominees to federal courts. During his first presidency, Trump installed more than 200 federal judges, including staffing nearly as many influential appellate court judges in one term as former president Barack Obama did in two, according to Pew Research . Trump appointed 54 appellate judges, one shy of Obama’s total. Trump also cemented the highest court’s conservative supermajority by appointing three justices in his first term. Biden has already appointed more than 200 federal judges but only one justice to the Supreme Court — the liberal Ketanji Brown Jackson. That did not affect the court’s ideological leaning. Now, the president wants to see Chuck Schumer, the Democratic senate majority leader, quickly approve as many Biden appointees as possible. “We’ve been working with them very, very closely to get as many of the president’s nominees confirmed because he believes that he wants to leave a lasting impact on the judiciary,” the White House official said.

Bobby Rusnak: A Pillar of Leadership and Resilience at Dickey's Barbecue Pit

Trump brings back government by social mediaTrump’s latest tariff plan aims at multiple countries. What does it mean for the US?

BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") OSUR , a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure's innovation pipeline with the addition of Sherlock's molecular diagnostics platform, which is able to provide rapid results with strong sensitivity and specificity in a disposable format that is well-suited for over-the-counter usage. Sherlock's first molecular self-test is for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) which will expand OraSure's portfolio of rapid diagnostics for sexually transmitted infections (STIs), subject to regulatory approvals. Test results are expected to be provided in under 30 minutes by analyzing DNA and RNA from self-collected swabs using isothermal amplification. In addition, Sherlock has been developing a pipeline of other molecular tests, along with several next-generation technology platforms, including Ambient Temperature Amplification and CRISPR-based technologies that have the potential to further reduce costs and improve performance of its platforms. Sherlock's CT/NG self-test is in clinical studies and is expected to be submitted to the FDA by the end of 2025 for review. Subject to regulatory approvals, revenue from Sherlock's CT/NG test is expected to contribute to OTI's growth beginning in 2026, benefitting from OraSure's existing infrastructure, commercial capabilities, and strong customer relationships. OTI estimates that testing for CT/NG represents a total addressable market of more than $1.5 billion. The vast majority of CT/NG tests in the U.S. are processed in a centralized lab, and the introduction of an affordable, rapid self-test has the potential to drive significant incremental market expansion. Additionally, public health channels play a key role in STI screening, which is an area where OraSure has a strong presence. "The acquisition of Sherlock represents the next step in OTI's innovation strategy," said Carrie Eglinton Manner, President and CEO of OraSure. "Sherlock brings valuable capabilities with an advanced molecular platform that aims to deliver lab-like accuracy in a format that expands access to diagnostic insights through convenient, effortless tests. We are excited to welcome Sherlock's talented team to OTI and believe that Sherlock's unique capabilities will contribute significantly to the expansion of our pipeline of diagnostic tests in infectious disease, sexual health, and beyond." Conference Call Information OraSure will host a conference call to discuss the acquisition of Sherlock Biosciences at 5:00 p.m. ET on Thursday, Dec. 19, 2024. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately 90 days. To participate in the live conference call, please follow the link below to pre-register. After registering, you will be provided with access details via email. https://register.vevent.com/register/BIb938f5bae2a442d9acdb83f4bdd9286d About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure") transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com Forward Looking Statements This press release contains certain "forward-looking statements" within the meaning of the Federal securities laws, including with respect to products, product development and manufacturing activities, the Company's acquisition of Sherlock, revenue growth, cash flow, increasing margins and other matters. Words such as "expects," "estimates," "forecasts," "intends," "plans," "projects," "could," "may," "should," "will" or other similar words and expressions are intended to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: the Company's ability to integrate Sherlock's business and achieve the intended benefits of the acquisition on the timeline expected or at all; Sherlock's ability to seek and obtain regulatory approval for products in development; the Company's ability to satisfy customer demand; ability to reduce the Company's spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to achieve the anticipated cost savings as a result of the Company's business restructuring, including from insourcing third party manufacturing and exiting microbiome services; ability to market and sell products, whether through the Company's internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for the Company's products; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; the impact of the novel coronavirus ("COVID-19") pandemic on the Company's business, supply chain, labor force, ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing, and demand for the Company's COVID-19 testing products; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company's products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales and the ability to continue to reduce costs; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of the Company's products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company's stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; cybersecurity breaches or other attacks involving the Company's systems or those of the Company's third-party contractors and IT service providers; the impact of terrorist attacks, civil unrest, hostilities and war; and general political, business and economic conditions, including inflationary pressures and banking stability. These and other factors that could affect the Company's results are discussed more fully in the Company's filings with the Securities and Exchange Commission (the "SEC"), including the Company's registration statements, Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and the Company undertakes no duty to update these statements. Investor Contact: Media Contact: Jason Plagman Amy Koch VP, Investor Relations Director, Corporate Communications investorinfo@orasure.com media@orasure.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Parkland Co. ( TSE:PKI – Get Free Report ) has been given an average recommendation of “Buy” by the nine brokerages that are currently covering the firm, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is C$48.08. A number of analysts recently issued reports on the stock. Cormark decreased their price objective on shares of Parkland from C$53.00 to C$49.00 in a report on Friday, August 2nd. Scotiabank decreased their price target on shares of Parkland from C$60.00 to C$52.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Raymond James lowered their price target on shares of Parkland from C$55.00 to C$47.00 in a report on Friday, October 25th. BMO Capital Markets reduced their price objective on Parkland from C$49.00 to C$46.00 in a report on Tuesday, October 22nd. Finally, National Bankshares lowered their target price on Parkland from C$47.00 to C$45.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. View Our Latest Research Report on PKI Parkland Trading Down 1.6 % Parkland Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Tuesday, October 15th. Stockholders of record on Friday, September 20th were given a $0.35 dividend. The ex-dividend date of this dividend was Thursday, September 19th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 3.87%. Parkland’s dividend payout ratio (DPR) is currently 65.73%. Insider Activity at Parkland In other Parkland news, Director Michael Christian Jennings acquired 4,000 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were bought at an average price of C$32.02 per share, for a total transaction of C$128,060.00. 20.51% of the stock is owned by corporate insiders. Parkland Company Profile ( Get Free Report Parkland Corporation operates food and convenience stores in Canada, the United States, and internationally. The company’s Canada segment owns, supplies, and supports a coast-to-coast network of retail gas stations, electronic vehicle charging stations, frozen food retail locations, convenience stores, cardlock sites, bulk fuel, propane, heating oil, lubricants, and other related services to commercial, industrial, and residential customers; transports and distributes fuel through ships, rail, and highway carriers; and stores fuel in terminals and other owned and leased facilities, as well as engages in the low-carbon activities. Featured Stories Five stocks we like better than Parkland Upcoming IPO Stock Lockup Period, Explained The Latest 13F Filings Are In: See Where Big Money Is Flowing Manufacturing Stocks Investing 3 Penny Stocks Ready to Break Out in 2025 Canadian Penny Stocks: Can They Make You Rich? FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential Receive News & Ratings for Parkland Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parkland and related companies with MarketBeat.com's FREE daily email newsletter .

SALT LAKE CITY--(BUSINESS WIRE)--Dec 19, 2024-- Franklin Covey Co. (NYSE: FC), a leader in organizational performance improvement, announced today that the conference call to review the Company’s first quarter fiscal 2025 financial results will take place on Wednesday, January 8, 2025, at 5:00 p.m. ET (3:00 p.m. MT). The Company’s financial results are expected to be released after the close of the market on Wednesday, January 8, 2025. Interested persons may access a live webcast at https://edge.media-server.com/mmc/p/gk9ap76y or may participate via telephone by registering at https://register.vevent.com/register/BIe59413e64e764817b6ae5c75d8008324 . Once registered, participants will have the option of 1) dialing into the call from their phone (via a personalized PIN); or 2) clicking the “Call Me” option to receive an automated call directly to their phone. For either option, registration will be required to access the call. A replay of the conference call webcast will be archived on the Company’s website for at least 30 days. About Franklin Covey Co. Franklin Covey (NYSE: FC) is the most trusted leadership company in the world with operations in over 150 countries. We transform organizations by partnering with our clients to build leaders, teams, and cultures that get breakthrough results through collective action, which leads to a more engaging work experience for their people. Available through the Franklin Covey All Access Pass®, our best-in-class content and solutions, experts, technology, and metrics seamlessly integrate together to ensure lasting behavior change at scale. This approach to leadership and organizational change has been tested and refined by working with tens of thousands of teams and organizations over the past 30 years. View source version on businesswire.com : https://www.businesswire.com/news/home/20241219219776/en/ CONTACT: For Further Information: Stephen D. Young Chief Financial Officer 801-817-1776 KEYWORD: UTAH UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CONSULTING PROFESSIONAL SERVICES TRAINING HUMAN RESOURCES EDUCATION SOURCE: Franklin Covey Co. Copyright Business Wire 2024. PUB: 12/19/2024 04:03 PM/DISC: 12/19/2024 04:03 PM http://www.businesswire.com/news/home/20241219219776/en